Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09ORU
|
||||
| Former ID |
DIB009562
|
||||
| Drug Name |
ZELANDOPAM HYDROCHLORIDE
|
||||
| Synonyms |
MYD-37; YM-435; Zelandopam hydrochloride < Prop INNM >; (-)-(S)-4-(3,4-Dihydroxyphenyl)-1,2,3,4-tetrahydro-7,8-isoquinolinediol hydrochloride hydrate; (-)-(S)-4-(3,4-Dihydroxyphenyl)-7,8-dihydroxy-1,2,3,4-tetrahydroisoquinoline hydrochloride hydrate
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hypertension [ICD9: 401; ICD10:I10-I16] | Discontinued in Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H15NO4
|
||||
| Canonical SMILES |
C1C(C2=C(CN1)C(=C(C=C2)O)O)C3=CC(=C(C=C3)O)O
|
||||
| InChI |
1S/C15H15NO4/c17-12-3-1-8(5-14(12)19)10-6-16-7-11-9(10)2-4-13(18)15(11)20/h1-5,10,16-20H,6-7H2
|
||||
| InChIKey |
FULLEMQICAKPOE-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 119085-25-5
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Dopamine D1 receptor | Target Info | Antagonist | [2], [3] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Amphetamine addiction | |||||
| Morphine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Dopamine receptor mediated signaling pathway | ||||
| PathWhiz Pathway | Dopamine Activation of Neurological Reward System | ||||
| Reactome | Dopamine receptors | ||||
| G alpha (s) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002584) | ||||
| REF 2 | Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats. Eur J Pharmacol. 2005 Mar 7;510(1-2):121-6. | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.